Abstract

Medical product development (MPD) process is highly multidisciplinary in nature, which increases the complexity and the associated risks. Managing the risks during MPD process is very crucial. The objective of this research is to explore risks during MPD in a dental product manufacturing company and propose a model for risk mitigation during MPD process to minimize failure events. A case study approach is employed. The existing MPD process is mapped with five phases of the customized phase gate process. The activities during each phase of development and risks associated with each activity are identified and categorized based on the source of occurrence. The risks are analyzed using traditional Failure mode and effect analysis (FMEA) and fuzzy FMEA. The results of two methods when compared show that fuzzy approach avoids the duplication of RPNs and helps more to convert cognition of experts into information to get values of risk factors. The critical, moderate, low level and negligible risks are identified based on criticality; risk treatments and mitigation model are proposed. During initial phases of MPD, the risks are less severe, but as the process progresses the severity of risks goes on increasing. The MPD process should be critically designed and simulated to minimize the number of risk events and their severity. To successfully develop the products/devices within the manufacturing companies, the process risk management is very essential. A systematic approach to manage risks during MPD process will lead to the development of medical products with expected quality and reliability. This is the first research of its kind having focus on MPD process risks and its management. The methodology adopted in this paper will help the developers, managers and researchers to have a competitive edge over the other companies by managing the risks during the development process.

Highlights

  • Medical product development (MPD) process is highly multidisciplinary in nature, which increases the complexity and the associated risks

  • During initial phases of MPD, the risks are less severe, but as the process progresses the severity of risks goes on increasing

  • The risk management methodologies refer to a standard process presenting the well-known steps: risk identification, risk evaluation and quantification, risk mitigation for treatment and/or impact minimization and risk monitoring (Marmier et al 2013)

Read more

Summary

Introduction

Medical product development (MPD) process is highly multidisciplinary in nature, which increases the complexity and the associated risks. Bringing a new medical product successfully from the bench to beside is highly complex and depends heavily on the implementation of rigorous processes. These processes need to allow developers to optimally phase development, testing, and other activities, and to successfully execute on the manifold requirements of third parties, including regulators and payers. These additional requirements set medical product/device development apart from the development of other products (Pietzsch et al 2009).

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call